Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis

BMC Biotechnology

Arthur A DeCarlo³  Maria Belousova³  April L Ellis³  Donald Petersen³  Hernan Grenett³  Patrick Hardigan¹  Robert O’Grady²  Megan Lord²  John M Whitelock² 

[1] Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia

[2] Statistical Consulting Center, Nova Southeastern University, 3200 South University Dr, Ft. Lauderdale, FL, 33328, USA

[3] Agenta Biotechnologies, Inc, 1500 1st Ave. N., Unit 31, Birmingham, AL, 35203, USA

关键词: Perlecan;    Osteoblast;    Implant;    Bone graft;    TCP;    Proteoglycan;    Chondroitin sulfate;    Heparan sulfate;    BMP-2;    Osteogenesis;   

Others  :  1134854
DOI  :  10.1186/1472-6750-12-60

 received in 2012-01-30, accepted in 2012-08-08,  发布年份 2012

【 摘 要 】

Background

Many growth factors, such as bone morphogenetic protein (BMP)-2, have been shown to interact with polymers of sulfated disacharrides known as heparan sulfate (HS) glycosaminoglycans (GAGs), which are found on matrix and cell-surface proteoglycans throughout the body. HS GAGs, and some more highly sulfated forms of chondroitin sulfate (CS), regulate cell function by serving as co-factors, or co-receptors, in GF interactions with their receptors, and HS or CS GAGs have been shown to be necessary for inducing signaling and GF activity, even in the osteogenic lineage. Unlike recombinant proteins, however, HS and CS GAGs are quite heterogenous due, in large part, to post-translational addition, then removal, of sulfate groups to various positions along the GAG polymer. We have, therefore, investigated whether it would be feasible to deliver a DNA pro-drug to generate a soluble HS/CS proteoglycan in situ that would augment the activity of growth-factors, including BMP-2, in vivo.

Results

Utilizing a purified recombinant human perlecan domain 1 (rhPln.D1) expressed from HEK 293 cells with HS and CS GAGs, tight binding and dose-enhancement of rhBMP-2 activity was demonstrated in vitro. In vitro, the expressed rhPln.D1 was characterized by modification with sulfated HS and CS GAGs. Dose-enhancement of rhBMP-2 by a pln.D1 expression plasmid delivered together as a lyophilized single-phase on a particulate tricalcium phosphate scaffold for 6 or more weeks generated up to 9 fold more bone volume de novo on the maxillary ridge in a rat model than in control sites without the pln.D1 plasmid. Using a significantly lower BMP-2 dose, this combination provided more than 5 times as much maxillary ridge augmentation and greater density than rhBMP-2 delivered on a collagen sponge (InFuse™).

Conclusions

A recombinant HS/CS PG interacted strongly and functionally with BMP-2 in binding and cell-based assays, and, in vivo, the pln.247 expression plasmid significantly improved the dose-effectiveness of BMP-2 osteogenic activity for in vivo de novo bone generation when delivered together on a scaffold as a single-phase. The use of HS/CS PGs may be useful to augment GF therapeutics, and a plasmid-based approach has been shown here to be highly effective.

【 授权许可】

   
2012 DeCarlo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

Figure 12.

【 参考文献 】

• [1]Dombrowski C, Song SJ, Chuan P, Lim X, Susanto E, Sawyer AA, Woodruff MA, Hutmacher DW, Nurcombe V, Cool SM: Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells. Stem Cells Dev 2009, 18(4):661-670.
• [2]Allen BL, Rapraeger AC: Spatial and temporal expression of heparan sulfate in mouse development regulates FGF and FGF receptor assembly. J Cell Biol 2003, 163(3):637-648.
• [3]Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M: Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000, 6(3):743-750.
• [4]Ornitz DM: FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000, 22(2):108-112.
• [5]Wu ZL, Zhang L, Yabe T, Kuberan B, Beeler DL, Love A, Rosenberg RD: The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem 2003, 278(19):17121-17129.
• [6]Muthusamy A, Cooper CR, Gomes RR: Soluble Perlecan Domain I Enhances Vascular Endothelial Growth Factor-165 Activity and Receptor Phosphorylation in Human Bone Marrow Endothelial Cells. BMC Biochem 2010, 11(1):43. BioMed Central Full Text
• [7]Chuang CY, Lord MS, Melrose J, Rees MD, Knox SM, Freeman C, Iozzo RV, Whitelock JM: Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 2010, 49(26):5524-5532.
• [8]DeCarlo AA, Whitelock JM: The role of heparan sulfate and perlecan in bone-regenerative procedures. J Dent Res 2006, 85(2):122-132.
• [9]Cool S, Nurcombe V: Heparan sulfate regulation of progenitor cell fate. J Cell Biochem 2006, 99(4):1040-1051.
• [10]Lamoureux F: Baud’huin M, Duplomb L, Heymann D, Rédini F: Proteoglycans: key partners in bone cell biology. Bioessays 2007, 29(8):758-771.
• [11]Woodruff MA, Rath SN, Susanto E, Haupt LM, Hutmacher DW, Nurcombe V, Cool SM: Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model. J Mol Histol 2007, 38(5):425-433.
• [12]Yang W, Gomes RR, Brown AJ, Burdett AR, Alicknavitch M, Farach-Carson MC, Carson DD: Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng 2006, 12(7):2009-2024.
• [13]Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X: Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 2009, 30(36):6964-6975.
• [14]Takada T: Sulfated Polysaccharides Enhance the Biological Activities of Bone Morphogenetic Proteins. J Biol Chem 2003, 278(44):43229-43235.
• [15]Irie A, Habuchi H, Kimata K, Sanai Y: Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 2003, 308(4):858-865.
• [16]Ruppert R, Hoffmann E, Sebald W: Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996, 237(1):295-302.
• [17]Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996, 271:10079-10086.
• [18]Yang WD, Gomes RR Jr: Alicknavitch M, Farach-Carson MC, Carson DD: Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Tissue Eng 2005, 11(1–2):76-89.
• [19]Casper CL, Yang W, Farach-Carson MC, Rabolt JF: Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding. Biomacromolecules 2007, 8(4):1116-1123.
• [20]Deepa SS: Specific Molecular Interactions of Oversulfated Chondroitin Sulfate E with Various Heparin-binding Growth Factors. Implication as a physiological binding partner in the brain and other tissues. J Biol Chem 2002, 277(46):43707-43716.
• [21]Li F: Shetty AK. Sugahara K: Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. J Biol Chem 2007, 282(5):2956-2966.
• [22]Miyazaki T, Miyauchi S, Tawada A, Anada T, Matsuzaka S, Suzuki O: Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. J Cell Physiol 2008, 217(3):769-777.
• [23]Yasunori Shintani STYAHKYLSYOTOSHYTFKSMKMH: Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J 2006, 25(13):3045.
• [24]Whitelock JM, Iozzo RV: Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005, 105(7):2745-2764.
• [25]Ellis AL, Pan W, Yang G, Jones K, Chuang C, Whitelock JM, DeCarlo AA: Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1. BMC Biotechnol 2010, 10(66):10-66.
• [26]Qiu X, Schroeder P, Bridon D: Identification and characterization of a C(K/R)TC motif as a common epitope present in all subtypes of hepatitis B surface antigen. J Immunol 1996, 156:3350-3356.
• [27]Khan S, Rodriguez E, Patel R, Gor J, Mulloy B, Perkins SJ: The Solution Structure of Heparan Sulfate Differs from That of Heparin: Implications for Function. J Biol Chem 2011, 286(28):24842-24854.
• [28]Rudd TR, Uniewicz KA, Ori A, Guimond SE, Skidmore MA, Gaudesi D, Xu R, Turnbull JE, Guerrini M, Torri G, et al.: Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Org Biomol Chem 2010, 8(23):5390.
• [29]Abramsson A, Kurup S, Busse M, Yamada S, Lindblom P, Schallmeiner E, Stenzel D, Sauvaget D, Ledin J, Ringvall M, et al.: Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev 2007, 21(3):316-331.
• [30]Robinson CJ, Mulloy B, Gallagher JT, Stringer SE: VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 2006, 281(3):1731-1740.
• [31]van den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, Salmivirta M: Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem 2005, 280(21):20516-20523.
• [32]David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H: Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992, 119(4):961-975.
• [33]Deepa SS, Yamada S, Fukui S, Sugahara K: Structural determination of novel sulfated octasaccharides isolated from chondroitin sulfate of shark cartilage and their application for characterizing monoclonal antibody epitopes. Glycobiology 2007, 17(6):631-645.
• [34]Ito Y, Hikino M, Yajima Y, Mikami T, Sirko S, von Holst A, Faissner A, Fukui S, Sugahara K: Structural characterization of the epitopes of the monoclonal antibodies 473HD, CS-56, and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library. Glycobiology 2005, 15(6):593-603.
• [35]Gandhi NS, Mancera RL: Prediction of heparin binding sites in bone morphogenetic proteins (BMPs). Biochimica Et Biophysica Acta 2012,  : .
• [36]Kuboki Y, Takita H, Kobayashi D, Tsuruga E, Inoue M, Murata M, Nagai N, Dohi Y, Ohgushi H: BMP-induced osteogenesis on the surface of hydroxyapatite with geometrically feasible and nonfeasible structures: topology of osteogenesis. J Biomed Mater Res A 1998, 39(2):190-199.
• [37]Gao T, Lindholm TS, Marttinen A, Urist MR: Composites of bone morphogenetic protein (BMP) and type IV collagen, coral-derived coral hydroxyapatite, and tricalcium phosphate ceramics. Int Orthop 1996, 20(5):321-325.
• [38]Urist MR, Nilsson O, Rasmussen J, Hirota W, Lovell T, Schmalzreid T, Finerman GA: Bone regeneration under the influence of a bone morphogenetic protein (BMP) beta tricalcium phosphate (TCP) composite in skull trephine defects in dogs. Clin Orthop Relat Res 1987, 214:295-304.
• [39]Urist MR, Lietze A, Dawson E: Beta-tricalcium phosphate delivery system for bone morphogenetic protein. Clin Orthop Relat Res 1984, 187:277-280.
• [40]Knox S, Merry C, Stringer S, Melrose J, Whitelock J: Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem 2002, 277(17):14657-14565.
• [41]Eyckmans J, Roberts SJ, Schrooten J, Luyten FP: A clinically relevant model of osteoinduction: a process requiring calcium phosphate and BMP/Wnt signalling. J Cell Mol Med 2010, 14(6B):1845-1856.